Company intelligence / Profile preview
LimmaTech Biologics
Schlieren, Zurich, Switzerlandlmtbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
LimmaTech Biologics is a clinical-stage Swiss biotechnology company specializing in the development of next-generation vaccines to combat antimicrobial resistance and life-threatening bacterial infections. Spun out of GlycoVaxyn following its acquisition by GSK in 2015, the company leverages a proprietary enzymatic bioconjugation platform to create complex multivalent glycoconjugate vaccines. Its lead program is a vaccine candidate for Shigella, currently in Phase 2 clinical trials, which is being developed in collaboration with partners like Valneva. LimmaTech's pipeline also includes programs targeting Klebsiella pneumoniae and Staphylococcus aureus, aiming to address significant unmet medical needs in global health.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineBioconjugateRecombinant protein
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
GSKValnevaWellcome TrustCARB-X
Beyond the preview
Go deeper on LimmaTech Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LimmaTech Biologics.